GemVax Wins Minister of SMEs and Startups Award at the 60th Inventors' Day

GemVax & KAEL announced on May 20 that it received the Minister of SMEs and Startups Award at the 60th Inventors’ Day Commemoration Ceremony, which was hosted and organized by the Korean Intellectual Property Office and the Korea Invention Promotion Association.

The Inventors’ Day ceremony is an event that recognizes individuals who have made significant contributions to invention in various fields representing Korea, as well as those who have developed original and core technologies and achieved remarkable accomplishments. This year, the event was held at the COEX Magok Convention Center.

GemVax was recognized for its achievements in securing domestic and international patents for various indications, including Alzheimer’s disease and progressive supranuclear palsy (PSP), thereby contributing to establishing a global technological advantage in the new drug bio sector.

To date, GemVax has secured over 380 patents both domestically and internationally. More than 50 preclinical and clinical research papers related to new drugs have been published in major academic journals. In addition, the company has continuously presented research results at major academic conferences in Korea and abroad, attracting significant attention not only from academia but also from the research and industry sectors.

Last year, GemVax was selected for the “IP-Based Overseas Expansion Support (Global IP Star Company) Project” organized by the Korea Invention Promotion Association. Over three years, the company is receiving up to 210 million KRW in government support for overseas patent applications, registrations, and related activities.

GemVax is focusing its capabilities on drug development in the field of neurodegenerative diseases such as Alzheimer’s disease and progressive supranuclear palsy. The company is engaged in research and development at various stages, from basic research to clinical trials.

Recently, GemVax completed the first domestic Phase 2 clinical trial for PSP and is preparing for a global Phase 3 clinical trial based on the obtained data. For the Alzheimer’s disease treatment, the company successfully completed global Phase 2 clinical trials in seven countries, including the United States and several European nations, thereby increasing the potential for developing a new treatment.

A GemVax official stated, “It is a great honor to receive the Minister of SMEs and Startups Award at such an important event celebrating Korea’s inventions and technological innovation,” and added, “With this award as motivation, we will make even greater efforts to secure intellectual property rights not only in Korea but also overseas.” The official continued, “We will also do our utmost in the development of new drugs for neurodegenerative diseases.”